{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:31:45Z","timestamp":1776141105211,"version":"3.50.1"},"reference-count":40,"publisher":"American Physiological Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Physiology-Endocrinology and Metabolism"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:p> Studies using pharmacological gonadotropin stimulation suggest that ovarian steroidogenesis is abnormal in the polycystic ovary syndrome (PCOS). We assessed ovarian steroid secretion in response to near-physiological gonadotropin stimuli in 12 ovulatory controls and 7 women with PCOS. A gonadotropin-releasing hormone-receptor antagonist (ganirelix, 2 mg sc) was given to block endogenous LH secretion, followed by dexamethasone (0.75 mg orally) to suppress adrenal androgen secretion. After ganirelix injection (12 h), intravenous infusions of recombinant human LH (0, 10, 30, 100, and 300 IU; each over 8 min) were administered at 4-h intervals in a pseudorandomized (highest dose last) manner. Plasma LH, 17-hydroxyprogesterone (17-OHP), androstenedione, and testosterone were measured concurrently. LH dose-steroid response relationships (mean sex-steroid concentration vs. mean LH concentration over 4 h postinfusion) were examined for each subject. Linear regression of 17-OHP on LH yielded a higher (mean \u00b1 SE) slope in PCOS (0.028 \u00b1 0.010 vs. 0.005 \u00b1 0.005, P &lt; 0.05), whereas extrapolated 17-OHP at zero LH was similar. The slopes of other regressions did not differ from zero in either PCOS or controls. We conclude that near-physiological LH stimulation drives heightened 17-OHP secretion in patients with PCOS, suggesting abnormalities of early steps of ovarian steroidogenesis. With the exception of 17-OHP response in PCOS, no acute LH dose-ovarian steroid responses were observed in controls or PCOS. Defining the precise mechanistic basis of heightened precursor responsiveness to LH in PCOS will require further clinical investigation. <\/jats:p>","DOI":"10.1152\/ajpendo.00415.2003","type":"journal-article","created":{"date-parts":[[2004,5,12]],"date-time":"2004-05-12T17:23:36Z","timestamp":1084382616000},"page":"E902-E908","source":"Crossref","is-referenced-by-count":20,"title":["Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome"],"prefix":"10.1152","volume":"286","author":[{"given":"Christopher R.","family":"McCartney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy B.","family":"Bellows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa B.","family":"Gingrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes D.","family":"Veldhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"24","reference":[{"key":"R1","unstructured":"Ankarberg C and Norjavaara E. Diurnal rhythm of testosterone secretion before and throughout puberty in healthy girls: correlation with 17\u03b2-estradiol and dehydroepiandrosterone sulfate. J Clin Endocrinol Metab 84: 975\u2013984, 1999."},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198903023200904"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/16.6.1058"},{"key":"R4","unstructured":"Dunaif A. Insulin resistance and polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocr Rev 18: 774\u2013800, 1997."},{"key":"R5","unstructured":"Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, and Marshall JC. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 85: 4047\u20134052, 2000."},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Ehrmann D, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, and Polonsky KS. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82: 2108\u20132116, 1997.","DOI":"10.1210\/jc.82.7.2108"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Ehrmann DA, Barnes RB, and Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 16: 322\u2013353, 1995.","DOI":"10.1210\/er.16.3.322"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(01)02947-8"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111370"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.1450937.x"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1390621"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.2321049.x"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Gilling-Smith C, Willis DS, Beard RW, and Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 79: 1158\u20131165, 1994.","DOI":"10.1210\/jc.79.4.1158"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30181-6"},{"key":"R15","unstructured":"Ibanez L, Hall JE, Potau N, Carrascosa A, Prat A, and Taylor AE. Ovarian 17-hydroxyprogesterone hyper-responsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. J Clin Endocrinol Metab 81: 4103\u20134107, 1996."},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Jakubowicz DJ and Nestler JE. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab 82: 556\u2013560, 1997.","DOI":"10.1210\/jc.82.2.556"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/16.12.2546"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/15.1.21"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/12.7.1416"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(05)70071-2"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)57531-1"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1210\/mend.13.6.0311"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608293350902"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Nestler JE and Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 82: 4075\u20134079, 1997.","DOI":"10.1210\/jc.82.12.4075"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/16.4.608"},{"key":"R26","unstructured":"Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, and Marshall JC. Polycystic ovarian syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 83: 582\u2013590, 1998."},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.20.4.0374"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-7207(98)00177-4"},{"key":"R29","unstructured":"Rabinovici J, Rothman P, Monroe SE, Nerenberg C, and Jaffe RB. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing antagonist (ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. J Clin Endocrinol Metab 75: 1220\u20131225, 1992."},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Ropelato MG, Garcia-Rudaz C, Castro-Fernandez C, Ulloa-Aguirre A, Escobar ME, Barontini M, and Veldhuis JD. A preponderance of basic luteinizing hormone (LH) isoforms accompanies inappropriate hypersecretion of both basal and pulsatile LH in adolescents with polycystic ovarian syndrome. J Clin Endocrinol Metab 84: 4629\u20134636, 1999.","DOI":"10.1210\/jc.84.12.4629"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Rosenfield RL, Barnes RB, and Ehrmann DA. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 79: 1686\u20131692, 1994.","DOI":"10.1210\/jc.79.6.1686"},{"key":"R32","unstructured":"Rosner B. Fundamentals of Biostatistics (5th ed.). Pacific Grove, CA: Duxbury, 2000, p. 343\u2013347, 765\u2013767."},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00786.x"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Veldhuis JD, Pincus SM, Garcia-Rudaz MC, Ropelato MG, Escobar ME, and Barontini M. Disruption of the joint synchrony of luteinizing hormone, testosterone, and androstenedione secretion in adolescents with polycystic ovarian syndrome. J Clin Endocrinol Metab 86: 72\u201379, 2000.","DOI":"10.1210\/jcem.86.1.7125"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.3.8308"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1440619"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-66-1-165"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb02665.x"},{"key":"R39","unstructured":"Zawadski JK and Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Polycystic Ovary Syndrome. Current Issues in Endocrinology and Metabolism, edited by Dunaif A, Givens JR, Haseltine FP, and Merriam GR. Boston, MA: Blackwell, 1992, vol. 4, p. 377\u2013384."},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1210\/endo.141.8.7595"}],"container-title":["American Journal of Physiology-Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.physiology.org\/doi\/pdf\/10.1152\/ajpendo.00415.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T14:28:40Z","timestamp":1567952920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.physiology.org\/doi\/10.1152\/ajpendo.00415.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1152\/ajpendo.00415.2003"],"URL":"https:\/\/doi.org\/10.1152\/ajpendo.00415.2003","relation":{},"ISSN":["0193-1849","1522-1555"],"issn-type":[{"value":"0193-1849","type":"print"},{"value":"1522-1555","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}